Providence Medical Research Center, Providence Health Care, Spokane, Washington, USA; Institute of Translational Health Sciences, Kidney Research Institute, and Nephrology Division, University of Washington, Seattle, Washington, USA.
Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada; Nephrology Division, University of Toronto, Toronto, Ontario, Canada.
Kidney Int. 2021 Feb;99(2):301-303. doi: 10.1016/j.kint.2020.10.003.
Risks of kidney failure and heart failure are markedly reduced by inhibition of the sodium glucose cotransporter 2 (SGLT2) in patients with diabetic kidney disease. In a post hoc analysis of the Study of Diabetic Nephropathy with Atrasentan (SONAR) trial, drop-in SGLT2 inhibitor usage during the atrasentan enrichment period led to greater reduction in albuminuria compared with atrasentan alone. These data support the hypothesis of greater longer-term kidney protection by combination SGLT2 inhibition and endothelin A receptor antagonism that could be tested in future clinical trials.
抑制糖尿病肾病患者的钠-葡萄糖共转运蛋白 2（SGLT2）可显著降低肾衰竭和心力衰竭的风险。在阿托西班研究（SONAR）试验的事后分析中，与单独使用阿托西班相比，在阿托西班富集期内使用 SGLT2 抑制剂可导致蛋白尿进一步降低。这些数据支持 SGLT2 抑制与内皮素 A 受体拮抗联合应用可带来更长期肾脏保护作用的假说，未来临床试验可对此进行检验。
